SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Stattin Pär) "

Sökning: WFRF:(Stattin Pär)

  • Resultat 451-460 av 509
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
451.
  •  
452.
  •  
453.
  •  
454.
  • Van Hemelrijck, Mieke, et al. (författare)
  • Risk of thromboembolic diseases in men with prostate cancer : results from the population-based PCBaSe Sweden
  • 2010
  • Ingår i: The Lancet Oncology. - : Elsevier. - 1470-2045 .- 1474-5488. ; 11:5, s. 450-458
  • Tidskriftsartikel (refereegranskat)abstract
    • Background Cancer is associated with an increased risk of thromboembolic diseases, but data on the association between prostate cancer and thromboembolic diseases are scarce. We investigated the risk of thromboembolic disease in men with prostate cancer who were receiving endocrine treatment, curative treatment, or surveillance. Methods We analysed data from PCBaSe Sweden, a database based on the National Prostate Cancer Register, which covers over 96% of prostate cancer cases in Sweden. Standardised incidence ratios (SIR) of deep-venous thrombosis (DVT), pulmonary embolism, and arterial embolism were calculated by comparing observed and expected (using the total Swedish male population) occurrences of thromboembolic disease, taking into account age, calendar-time, number of thromboembolic diseases, and time since previous thromboembolic disease. Findings Between Jan 1, 1997, and Dec 31, 2007, 30 642 men received primary endocrine therapy, 26 432 curative treatment, and 19 526 surveillance. 1881 developed a thromboembolic disease. For men on endocrine therapy, risks for DVT (SIR 2·48, 95% CI 2·25–2·73) and pulmonary embolism (1·95, 1·81–2·15) were increased, although this was not the case for arterial embolism (1·00, 0·82–1·20). Similar patterns were seen for men who received curative treatment (DVT: 1·73, 1·47–2·01; pulmonary embolism: 2·03, 1·79–2·30; arterial embolism: 0·95, 0·69–1·27) and men who were on surveillance (DVT: 1·27, 1·08–1·47; pulmonary embolism: 1·57, 1·38–1·78; arterial embolism: 1·08, 0·87–1·33). Increased risks for thromboembolic disease were maintained when patients were stratified by age and tumour stage. Interpretation All men with prostate cancer were at higher risk of thromboembolic diseases, with the highest risk for those on endocrine therapy. Our results indicate that prostate cancer itself, prostate cancer treatments, and selection mechanisms all contribute to increased risk of thromboembolic disease. Thromboembolic disease should be a concern when managing patients with prostate cancer.
  •  
455.
  • Van Hemelrijck, Mieke, et al. (författare)
  • Thromboembolic events following surgery for prostate cancer
  • 2013
  • Ingår i: European Urology. - : Elsevier. - 0302-2838 .- 1873-7560. ; 63:2, s. 354-363
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: Prostate cancer (PCa) and surgery are both associated with increased risk of thromboembolic diseases (TED). Objective: We assessed risk of TED among men undergoing different types of urologic surgery. Design, setting, and participants: Using the Prostate Cancer Database Sweden (PCBaSe) Sweden, we identified all men (n = 45 065) undergoing pelvic lymph node dissection (PLND), radical prostatectomy (RP) with or without PLND, orchiectomy due to PCa, or a transurethral resection of the prostate (TURP). We identified a comparison cohort from the population. Outcome measurements and statistical analysis: Main outcomes were deep venous thrombosis (DVT) and pulmonary embolism (PE) as primary diagnoses in the National Patient Register or Cause of Death Register (2002-2010). We calculated hazard ratios (HR) and 95% confidence intervals (CI) using multivariable Cox proportional hazards models. Results and limitations: All surgical procedures were associated with increased risk of TED; laparoscopic and open RP with a PLND were the most strongly associated with TED (HR for PE: 8.1 [95% CI, 2.9-23.0] and 7.8 [95% CI, 4.9-13], respectively). For surgery including a PLND, the risk increased during the second half of the first postoperative month. The HR for PE after TURP in men with PCa was 3.0 (95% CI, 1.8-5.1). Patients with a history of TED had a strongly increased risk of TED (HR for DVT: 4.5; 95% CI, 2.6-8.0). A limitation is lack of information on TED prophylaxis, but its use was standardized during the study period for RP and PLND. Other limitations are lack of information on extent of PLND and lifestyle factors. Conclusions: Surgeries for PCa, including TURP, are associated with hospitalization for TED. Patients with a history of TED and patients undergoing a PLND were at highest risk. The largest risk was observed from days 14 to 28 postoperatively. Thus, our results suggest that prophylactic measures may be beneficial during the first 4 wk in these patients. (C) 2012 European Association of Urology. Published by Elsevier B. V. All rights reserved.
  •  
456.
  •  
457.
  •  
458.
  • Varenhorst, Eberhard, 1937-, et al. (författare)
  • The National Prostate Cancer Register in Sweden 1998-2002 : trends in incidence, treatment and survival
  • 2005
  • Ingår i: Scandinavian Journal of Urology and Nephrology. - : Informa UK Limited. - 0036-5599 .- 1651-2065. ; 39:2, s. 117-123
  • Tidskriftsartikel (refereegranskat)abstract
    • OBJECTIVES: To provide a descriptive review of the establishment of the National Prostate Cancer Register (NPCR) in Sweden, to present clinical characteristics at diagnosis and to calculate the relative survival of different risk groups after 5 years. MATERIAL AND METHODS: Since 1998, data on all newly diagnosed prostate cancers, including TNM classification, grade of malignancy, prostate-specific antigen (PSA) level and treatment, have been prospectively collected. For the 35,223 patients diagnosed between 1998 and 2002, relative survival in different risk groups has been calculated. RESULTS: Between 1998 and 2002, 96% of all prostate cancer cases diagnosed in Sweden were registered in the NPCR. The number of new cases increased from 6137 in 1998 to 7385 in 2002. The age-standardized rate rose in those aged < 70 years, while it was stable, or possibly declining from 1999, in the older age groups. The proportion of T1c tumours increased from 14% to 28% of all recorded cases. The age-adjusted incidence of advanced tumours (M1 or PSA > 100 ng/ml) decreased by 17%. The proportion of patients receiving curative treatment doubled. Patients with N1 or M1 disease or poorly differentiated tumours (G3 or Gleason score 8-10) had a markedly reduced relative 5-year survival rate. CONCLUSIONS: It is possible to establish a nationwide prostate cancer register including basic data for assessment of the disease in the whole of Sweden. The introduction of PSA screening has increased the detection of early prostate cancer in younger men and, to a lesser extent, decreased the incidence of advanced disease. The effect of these changes on mortality is obscure but the NPCR in Sweden will serve as an important tool in such evaluation.
  •  
459.
  • Vellekoop, Annelies, et al. (författare)
  • Population Based Study of Predictors of Adverse Pathology among Candidates for Active Surveillance with Gleason 6 Prostate Cancer
  • 2014
  • Ingår i: Journal of Urology. - : Ovid Technologies (Wolters Kluwer Health). - 0022-5347 .- 1527-3792. ; 191:2, s. 350-357
  • Tidskriftsartikel (refereegranskat)abstract
    • PurposeApproximately a third of prostate cancer cases with a Gleason score of 6 are upgraded at radical prostatectomy. We studied trends and predictors of upgrading and up staging among men with Gleason 6 prostate cancer who were potential candidates for active surveillance in a population based cohort.Materials and MethodsFrom 2007 to 2011, 13,159 men were diagnosed with Gleason 6, clinical stage T1c/T2 prostate cancer in the NPCR (National Prostate Cancer Register of Sweden). Of these men 4,500 underwent radical prostatectomy, including 2,205 with data on the extent of prostate cancer in the biopsy cores. Logistic regression was used to examine variables associated with adverse pathology (defined as upgrading to Gleason 7 or greater, or up staging to pT3 or greater) in the full group and in potential candidates for active surveillance using 6 current published protocols.ResultsAmong Swedish men with clinically localized Gleason 6 prostate cancer approximately 50% had adverse pathology at radical prostatectomy. Of the men who met the study inclusion criteria of 6 different active surveillance protocols, adverse pathology was present in 33% to 45%. Predictors of adverse pathology were older age, higher prostate specific antigen, prostate specific antigen density greater than 0.15 ng/ml/cm3, palpable disease and extent of cancer greater than 4 mm on biopsy. Larger prostate volume had an inverse relationship with adverse pathology.ConclusionsMore than a third of men meeting the most stringent active surveillance criteria had adverse pathology at radical prostatectomy in this population based cohort. Active surveillance programs should consider prostate specific antigen density and extent of cancer on biopsy for patient selection.
  •  
460.
  • Ventimiglia, Eugenio, et al. (författare)
  • How to measure temporal changes in care pathways for chronic diseases using health care registry data
  • 2019
  • Ingår i: BMC Medical Informatics and Decision Making. - : BMC. - 1472-6947. ; 19
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: Disease trajectories for chronic diseases can span over several decades, with several time-dependent factors affecting treatment decisions. Thus, there is a need for long-term predictions of disease trajectories to inform patients and healthcare professionals on the long-term outcomes and provide information on the need of future health care. Here, we propose a state transition model to describe and predict disease trajectories up to 25 years after diagnosis in men with prostate cancer (PCa), as a proof of principle. Methods: States, state transitions, and transition probabilities were identified and estimated in Prostate Cancer data Base of Sweden (PCBaSeTraject), using nationwide population-based data from 118,743 men diagnosed with PCa. A state transition model in discrete time steps (i.e., 4 weeks) was developed and applied to capture all possible transitions (PCBaSeSim). Transition probabilities were estimated for changes in both treatment and comorbidity. These models combined yielded parameter estimates to run an individual-level simulation based on the state-transition model to obtain prediction estimates. Predicted estimates were then compared to real world data in PCBaSeTraject. Results: PCBaSeSim estimates for the cumulative incidence of first and second transitions, death from PCa and death from other causes were compared to observed transitions in PCBaSeTraject. A good agreement was found between simulated and observed estimates. Conclusions: We developed a reliable and accurate simulation tool, PCBaSeSim that provides information on disease trajectories for subjects with a chronic disease on an individual and population-based level.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 451-460 av 509
Typ av publikation
tidskriftsartikel (471)
doktorsavhandling (14)
annan publikation (13)
konferensbidrag (5)
forskningsöversikt (5)
licentiatavhandling (1)
visa fler...
visa färre...
Typ av innehåll
refereegranskat (433)
övrigt vetenskapligt/konstnärligt (73)
populärvet., debatt m.m. (3)
Författare/redaktör
Stattin, Pär (496)
Garmo, Hans (124)
Hallmans, Göran (75)
Adolfsson, Jan (63)
Robinson, David (60)
Kaaks, Rudolf (58)
visa fler...
Holmberg, Lars (56)
Häggström, Christel (53)
Bergh, Anders (51)
Stocks, Tanja (48)
Van Hemelrijck, Miek ... (46)
Manjer, Jonas (38)
Egevad, Lars (38)
Jonsson, Håkan (37)
Lambe, Mats (36)
Bratt, Ola (36)
Ulmer, Hanno (35)
Riboli, Elio (34)
Loeb, Stacy (34)
Bill-Axelson, Anna (31)
Nagel, Gabriele (31)
Engeland, Anders (30)
Wiklund, Fredrik (30)
Grönberg, Henrik (29)
Key, Timothy J (28)
Johansson, Mattias (28)
Allen, Naomi E (27)
Concin, Hans (27)
Tretli, Steinar (26)
Travis, Ruth C (25)
Folkvaljon, Yasin (25)
Lukanova, Annekatrin (24)
Rinaldi, Sabina (24)
Bueno-de-Mesquita, H ... (24)
Styrke, Johan (24)
Tumino, Rosario (23)
Selmer, Randi (23)
Boeing, Heiner (22)
Trichopoulou, Antoni ... (22)
Adami, Hans Olov (22)
Björge, Tone (22)
Franck-Lissbrant, In ... (22)
Palli, Domenico (21)
Xu, Jianfeng (21)
Overvad, Kim (20)
Khaw, Kay-Tee (20)
Widmark, Anders (20)
Appleby, Paul N. (20)
Gedeborg, Rolf (19)
Akre, Olof (19)
visa färre...
Lärosäte
Umeå universitet (398)
Uppsala universitet (288)
Karolinska Institutet (221)
Lunds universitet (122)
Göteborgs universitet (67)
Mälardalens universitet (17)
visa fler...
Örebro universitet (14)
Linköpings universitet (7)
Chalmers tekniska högskola (2)
Sveriges Lantbruksuniversitet (1)
visa färre...
Språk
Engelska (494)
Svenska (14)
Odefinierat språk (1)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (428)
Naturvetenskap (9)
Lantbruksvetenskap (7)
Samhällsvetenskap (1)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy